← Back to Clinical Trials
Recruiting NCT06000774

NCT06000774 Therapeutic Ketogenic Diet in Anorexia Nervosa

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06000774
Status Recruiting
Phase
Sponsor University of California, San Diego
Condition Anorexia Nervosa in Remission
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2023-10-03
Primary Completion 2027-06

Trial Parameters

Condition Anorexia Nervosa in Remission
Sponsor University of California, San Diego
Study Type INTERVENTIONAL
Phase N/A
Enrollment 20
Sex ALL
Min Age 18 Years
Max Age 45 Years
Start Date 2023-10-03
Completion 2027-06
Interventions
Therapeutic Ketogenic Diet

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This study will investigate the effects of therapeutic ketogenic diet (TKD) on eating behavior including drive to restrict, body dissatisfaction, mood and anxiety in individuals with anorexia nervosa who have been weight normalized (body mass index of 17.5 or greater) but continue to struggle with eating disorder behaviors including a high drive for thinness and body dissatisfaction. The Underweight Anorexia Nervosa (AN) Sub-Study will investigate the effects of TKD on eating behavior including drive to restrict, body dissatisfaction, mood and anxiety in individuals with anorexia nervosa who are currently underweight (body mass index between 16.0 and 17.49) and continue to struggle with eating disorder behaviors including a high drive for thinness and body dissatisfaction. The Bulimia Nervosa Pilot will will investigate the effects of TKD on eating behavior including drive to binge and purge, body dissatisfaction, mood and anxiety in individuals with bulimia nervosa.

Eligibility Criteria

Weight-Recovered AN Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Persons, aged 18 to 45 years 4. History of anorexia nervosa according to DSM-5 criteria 5. Weight recovered at the time of study inclusion (body mass index \> 17.5 kg/m2) 6. Greater or equal to 2 standard deviations scores of eating disorder-relevant behaviors on the Eating Disorder Inventory-3 and Eating Disorder Examination Questionnaire 7. The following types of psychiatric medications are allowed: antidepressant, anxiolytic, atypical antipsychotic, mood stabilizers 8. English is primary spoken language Weight-Recovered AN Exclusion Criteria: 1. Pregnancy or lactation 2. Electrolyte, blood count, kidney function or liver function abnormalities 3. Psychosis 4. Neurocognitive disorders including dementias or traumatic brain injury that is symptomatic 5. Current alcohol use disorder (AU

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology